Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
718 (USA) · Dr. Nolan
consented 2013-02-01
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE DERMATITIS — outcome: RECOVERED/RESOLVED; onset 2013-03-23 (study day 51.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE IRRITATION — outcome: RECOVERED/RESOLVED; onset 2013-03-23 (study day 51.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-02 (study day 61.0); relationship: PROBABLE
moderate
assessed
Moderate APPLICATION SITE IRRITATION — outcome: RECOVERED/RESOLVED; onset 2013-04-02 (study day 61.0); relationship: PROBABLE
Data queries
No data queries.